Dear Researchers, The Innovative Medicines Initiative (IMI) 2- call 20 is open for proposals. Eligible applicants are consortia with a minimum of 3 research teams (organizations) from 3 different EU-countries or associated countries. Applicants can be universities, research institutions, hospitals etc. It is encouraged to include SMEs which will also get funding through the project. The call is a standard two-stage call for proposals with the following topics: § Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis § Topic 2: Innovations to accelerate vaccine development and manufacture § Topic 3: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB) This topic is part of the IMI AMR Accelerator Programmehttps://www.imi.europa.eu/projects-results/project-factsheets/amr-accelerator. § Topic 4: Tumour plasticity § Topic 5: Proton versus photon therapy for oesophageal cancer - a trimodality strategy § Topic 6: Handling of protein drug products and stability concerns Deadline for short proposals: 21 April 2020. Call web page: http://bit.ly/imi2call20
Webinars
IMI is currently running webinarshttp://bit.ly/2S39Eob on IMI2 - Call 10, including webinars on all Call topics, as well as IMI's rules and procedures and opportunities for small and medium-sized enterprises (SMEs).
Tips on finding partners and preparing your proposal The IMI website includes pages with advice for applicantshttp://www.imi.europa.eu/apply-funding/general-overview/tips-applicants and guidance on how to find project partnershttp://www.imi.europa.eu/apply-funding/general-overview/finding-partners.
Best regards, Emma
************************ Emma Pirilä, PhD Research Funding Specialist Faculty of Medicine Faculty of Biochemistry and Molecular Medicine Biocenter Oulu Aapistie 5A, 2nd floor FIN- 90230 University of Oulu Finland Phone: +358503426428 e-mail: emma.pirila@oulu.fimailto:emma.pirila@oulu.fi ************************